GO:0050591 quinine 3-monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050591 quinine 3-monooxygenase activity is a cytochrome P450 monooxygenase activity that converts quinine to 3-hydroxyquinine using NADPH and O2.
• The activity is classically associated with CYP3A4, a major human drug-metabolizing enzyme, and is often measured as quinine 3-hydroxylation.
• CYP3A4 is the dominant CYP3A isoform in adult human liver and contributes to the metabolism of many drugs, including anticancer agents.
• CYP3A4 expression is regulated by nuclear receptors such as PXR and can be induced by rifampicin; METTL3 modulates this induction.
• Nitric oxide can modulate CYP2D6 and CYP3A4 activity in a concentration-dependent manner by affecting heme loading.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the role of CYP3A4 and related genes in quinine 3-monooxygenase activity.
Description
Quinine 3-monooxygenase activity (GO:0050591) is a molecular function defined by the catalytic conversion of quinine to 3-hydroxyquinine with concomitant consumption of NADPH and O2 and production of NADP+ and H2O. This activity is a classic marker for cytochrome P450 3A4 (CYP3A4), a heme-thiolate monooxygenase that is highly expressed in human liver and intestine and is responsible for the oxidative metabolism of a large fraction of clinical drugs. Because quinine 3-hydroxylation is relatively specific for CYP3A4, it has been widely used as a probe reaction to assess CYP3A4 activity in vitro and in vivo. Understanding the regulation and catalytic mechanism of this activity is therefore critical for predicting drug-drug interactions, optimizing drug dosing, and interpreting interindividual variability in drug response. The activity also serves as a model for studying the broader family of cytochrome P450 monooxygenases, which share a common catalytic cycle involving substrate binding, heme iron reduction, oxygen activation, and product release. In this article, we integrate the QuickGO definition with verified literature to provide a research-grade overview of quinine 3-monooxygenase activity, its key genes, regulatory mechanisms, disease relevance, and the experimental models used to study it.
quinine 3-monooxygenase activity At A Glance
| GO ID | GO:0050591 |
|---|---|
| GO term | quinine 3-monooxygenase activity |
| Ontology | molecular_function |
| Synonym | nifedipine oxidase activity; quinine 3-hydroxylase activity; quinine,NADPH:oxygen oxidoreductase activity |
| Major function | Catalyzes the 3-hydroxylation of quinine using NADPH and O2, producing 3-hydroxyquinine, NADP+, and H2O |
| Reaction | H+ + NADPH + O2 + quinine = 3-hydroxyquinine + H2O + NADP+ |
| Cofactors | NADPH, molecular oxygen, heme iron (cytochrome P450) |
| Representative enzyme | CYP3A4 (cytochrome P450 3A4) |
| Subcellular location | Endoplasmic reticulum membrane (cytochrome P450 enzymes) |
What Is GO:0050591?
Quinine 3-monooxygenase activity (GO:0050591) is defined as the catalysis of the reaction: H+ + NADPH + O2 + quinine = 3-hydroxyquinine + H2O + NADP+. In simpler terms, it is an enzymatic activity that adds a hydroxyl group to quinine at the 3-position, using NADPH as the electron donor and molecular oxygen as the oxygen source. This reaction is characteristic of certain cytochrome P450 enzymes, particularly CYP3A4, and is often referred to as quinine 3-hydroxylase activity. The activity is a monooxygenase reaction because one atom of molecular oxygen is incorporated into the substrate (quinine) while the other is reduced to water.
Why Is quinine 3-monooxygenase activity Important in Cell Biology?
Quinine 3-monooxygenase activity is important because it serves as a sensitive and relatively specific probe for CYP3A4, the most abundant cytochrome P450 in human liver and a key determinant of drug clearance. Alterations in CYP3A4 activity can lead to clinically significant drug-drug interactions, therapeutic failure, or toxicity, as exemplified by statin-related myotoxicity and the metabolism of anticancer drugs. Moreover, the activity is a model for understanding the catalytic mechanism of cytochrome P450 monooxygenases, which are involved in the metabolism of endogenous compounds such as steroids and fatty acids as well as xenobiotics. Studying quinine 3-monooxygenase activity therefore has direct implications for pharmacology, toxicology, and personalized medicine.
• Serves as a probe for CYP3A4 activity, a major drug-metabolizing enzyme.
• Helps predict drug-drug interactions involving CYP3A4 substrates and inhibitors.
• Relevant to statin-related myotoxicity, as statins are metabolized by CYP3A4.
• Contributes to the metabolism of anticancer drugs, influencing personalized cancer therapy.
• Provides a model for studying cytochrome P450 monooxygenase catalytic mechanisms.
• Regulated by nuclear receptors such as PXR, linking xenobiotic exposure to enzyme induction.
• Modulated by nitric oxide, which affects heme loading and enzyme activity.
• Used in microengineered liver cultures for drug development and toxicity testing.
• Can be studied using humanized mouse models expressing human CYP3A4.
• Suppression by compounds like 3-methylcholanthrene highlights species-specific regulation.
Molecular Mechanism of quinine 3-monooxygenase activity
Substrate binding and spin-state transition
In simple terms: The enzyme first grabs the quinine molecule, which changes the state of its heme iron.
In the catalytic cycle of cytochrome P450 enzymes such as CYP3A4, substrate binding to the active site displaces a water molecule coordinated to the heme iron, causing a low-spin to high-spin transition that facilitates subsequent electron transfer. This step is essential for the monooxygenase reaction and is often rate-limiting for quinine 3-hydroxylation.
First electron transfer from NADPH via CPR
In simple terms: A partner protein delivers an electron from NADPH to the heme iron.
NADPH-cytochrome P450 reductase (CPR) transfers the first electron to the heme iron, reducing it from ferric (Fe3+) to ferrous (Fe2+) state. This reduction is a prerequisite for oxygen binding and activation.
Oxygen binding and second electron transfer
In simple terms: Oxygen binds to the iron, and a second electron is added to form a reactive intermediate.
Molecular oxygen binds to the ferrous heme iron, forming an oxy-ferrous complex. A second electron, also supplied by CPR or cytochrome b5, reduces this complex to a ferric-peroxo species, which then undergoes protonation and cleavage of the O-O bond to generate a highly reactive ferryl-oxo (Compound I) intermediate.
Hydroxylation of quinine and product release
In simple terms: The reactive oxygen species inserts an oxygen atom into quinine, making 3-hydroxyquinine, which is then released.
The ferryl-oxo intermediate abstracts a hydrogen atom from quinine, followed by oxygen rebound to form 3-hydroxyquinine. The product is released, and the enzyme returns to its resting state, ready for another catalytic cycle.
Regulation by heme loading and nitric oxide
In simple terms: The amount of heme in the enzyme and signals like nitric oxide can change how well it works.
Nitric oxide can modulate CYP3A4 activity in a concentration-dependent manner by affecting heme loading, thereby influencing quinine 3-monooxygenase activity. Additionally, anion-dependent stimulation of CYP3A4 monooxygenase activity has been observed, suggesting that cellular ions can fine-tune catalysis.
Key Genes Involved in GO:0050591 quinine 3-monooxygenase activity
The following genes and proteins are directly or indirectly involved in quinine 3-monooxygenase activity, either as the catalytic enzyme, electron transfer partners, or regulators of expression and activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP3A4 | Primary enzyme catalyzing quinine 3-hydroxylation | Major drug-metabolizing enzyme; target for drug interaction studies |
| CYP3A5 | Closely related CYP3A isoform with overlapping substrate specificity | Genetic polymorphisms affect drug metabolism |
| CYP3A7 | Fetal CYP3A isoform | Developmental regulation and drug metabolism |
| POR | NADPH-cytochrome P450 reductase; transfers electrons to CYP3A4 | Essential for catalytic activity; genetic variants affect drug metabolism |
| CYB5A | Cytochrome b5; can donate electrons to some P450s | Modulates CYP3A4 activity |
| PXR (NR1I2) | Nuclear receptor regulating CYP3A4 transcription | Mediates rifampicin-induced CYP3A4 expression |
| CAR (NR1I3) | Nuclear receptor regulating CYP3A4 and other CYPs | Xenobiotic induction of drug metabolism |
| METTL3 | RNA methyltransferase stabilizing CYP3A4 mRNA | Regulates rifampicin-induced CYP3A4 expression |
| HNF4A | Hepatocyte nuclear factor 4 alpha; liver-enriched transcription factor | Regulates hepatic CYP3A4 expression |
| NRF2 | Oxidative stress-responsive transcription factor | May influence CYP3A4 expression under stress |
| NF-kB | Inflammatory transcription factor | Inflammation-mediated downregulation of CYP3A4 |
| IL-6 | Pro-inflammatory cytokine | Suppresses CYP3A4 expression during inflammation |
| TNF-alpha | Pro-inflammatory cytokine | Downregulates CYP3A4 activity |
| HNF1A | Transcription factor involved in liver-specific gene expression | Regulates CYP3A4 and other drug-metabolizing enzymes |
| GATA4 | Transcription factor | Modulates CYP3A4 expression in intestine and liver |
| CYP2D6 | Another cytochrome P450 enzyme | Nitric oxide modulates its activity similarly to CYP3A4 |
| CYP3A4*22 | Common genetic variant of CYP3A4 | Associated with reduced enzyme activity and drug response |
How Is quinine 3-monooxygenase activity Regulated?
Quinine 3-monooxygenase activity is regulated at multiple levels. Transcriptionally, CYP3A4 expression is induced by xenobiotics such as rifampicin through activation of the pregnane X receptor (PXR), which binds to response elements in the CYP3A4 promoter. METTL3, an RNA methyltransferase, regulates rifampicin-induced CYP3A4 expression by activating PXR translation and nuclear import and stabilizing CYP3A4 mRNA. Post-transcriptionally, CYP3A4 mRNA stability and translation can be influenced by microRNAs and RNA-binding proteins. At the protein level, heme availability is critical for CYP3A4 activity, and nitric oxide can modulate heme loading in a concentration-dependent manner, thereby affecting quinine 3-monooxygenase activity. Additionally, anion-dependent stimulation of CYP3A4 monooxygenase activity has been reported, suggesting that cellular ionic conditions can regulate catalysis. Inflammatory cytokines such as IL-6 and TNF-alpha downregulate CYP3A4 expression, linking inflammation to altered drug metabolism.
quinine 3-monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP3A4 | Statin-related myotoxicity | CYP3A4 knockout hepatocytes or humanized mice |
| CYP3A4 | Cancer drug resistance | CYP3A4 overexpression in cancer cell lines |
| CYP3A4 | Drug-drug interactions | Primary human hepatocytes treated with inducers/inhibitors |
| PXR (NR1I2) | Altered drug metabolism | PXR knockout or knock-in models |
| METTL3 | Rifampicin-induced CYP3A4 expression | METTL3 knockout or knockdown hepatocytes |
Statin-related myotoxicity
Statins are metabolized by CYP3A4, and alterations in CYP3A4 activity can lead to increased statin exposure and myotoxicity. Quinine 3-monooxygenase activity serves as a probe for CYP3A4 function, helping to predict individuals at risk for statin-related adverse effects.
Cancer therapy and drug metabolism
CYP3A4 metabolizes many anticancer drugs, and variability in its activity can influence therapeutic efficacy and toxicity. Quinine 3-monooxygenase activity is used to assess CYP3A4 function in cancer patients, guiding personalized dosing strategies.
Drug-drug interactions
Because CYP3A4 is involved in the metabolism of a large number of drugs, changes in quinine 3-monooxygenase activity can predict clinically significant drug-drug interactions. Inducers or inhibitors of CYP3A4 can alter the clearance of co-administered drugs, leading to therapeutic failure or toxicity.
Inflammation and infection
Inflammatory cytokines such as IL-6 and TNF-alpha downregulate CYP3A4 expression, potentially reducing quinine 3-monooxygenase activity during infection or chronic inflammatory conditions. This can affect the metabolism of drugs used to treat infections and other diseases.
From quinine 3-monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CYP3A4 knockout abolish quinine 3-monooxygenase activity? | CYP3A4 knockout HepG2 or primary hepatocytes |
| Does a specific CYP3A4 point mutation alter catalytic activity? | Point mutation knock-in via CRISPR in cell lines |
| Can we tag CYP3A4 to track its localization? | Knock-in of fluorescent or epitope tag at CYP3A4 locus |
| Does overexpression of CYP3A4 increase quinine 3-hydroxylation? | CYP3A4 overexpression in HEK293 or HepG2 cells |
| How does PXR regulate CYP3A4 induction? | PXR knockout or overexpression in hepatocytes |
| What is the role of METTL3 in CYP3A4 mRNA stability? | METTL3 knockout or knockdown in liver cells |
How to Study the quinine 3-monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | 3-hydroxyquinine formation | Quantifying CYP3A4 activity in microsomes or cells |
| RT-qPCR | CYP3A4 mRNA levels | Assessing transcriptional regulation |
| Western blot | CYP3A4 protein levels | Evaluating expression changes |
| CRISPR knockout | Loss of gene function | Determining causal role of CYP3A4 or regulators |
| CRISPR knock-in | Tagged or mutant protein expression | Tracking localization or function |
| RNA-seq | Global transcriptome changes | Identifying pathways co-regulated with CYP3A4 |
| Microengineered liver culture | Hepatocyte function and drug metabolism | Drug development and toxicity testing |
Enzyme activity assays
Quinine 3-monooxygenase activity is typically measured using quinine as substrate and NADPH as cofactor, followed by quantification of 3-hydroxyquinine by HPLC or LC-MS/MS. These assays can be performed with recombinant CYP3A4, liver microsomes, or intact cells.
Gene expression analysis
CYP3A4 mRNA levels can be quantified by RT-qPCR or RNA-seq to assess transcriptional regulation by PXR, CAR, and other factors. Protein levels can be measured by Western blotting or mass spectrometry.
CRISPR-based genome editing
CRISPR/Cas9 can be used to generate knockout, point mutation, or knock-in models to study the function of CYP3A4 and its regulators. These models allow causal inference about the role of specific genes in quinine 3-monooxygenase activity.
Microengineered liver cultures
Microengineered cultures containing human hepatic stellate cells and hepatocytes provide a physiologically relevant platform for drug development and can be used to study CYP3A4 activity and its regulation.
How CRISPR Can Be Used to Study GO:0050591 quinine 3-monooxygenase activity
Knockout
CRISPR/Cas9-mediated knockout of CYP3A4 in hepatocyte cell lines or primary cells can abolish quinine 3-monooxygenase activity, providing direct evidence for its role. Knockout of regulators such as PXR or METTL3 can reveal their contribution to CYP3A4 expression and activity.
Point Mutation
Introducing specific point mutations into CYP3A4 (e.g., active site residues or variants like CYP3A4*22) using CRISPR base editing or homology-directed repair can help dissect catalytic mechanism and allelic differences in quinine 3-monooxygenase activity.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at the endogenous CYP3A4 locus allows real-time tracking of enzyme localization and turnover in living cells. Knock-in of human CYP3A4 into mouse models can create humanized systems for drug metabolism studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CYP3A4 can increase quinine 3-monooxygenase activity, enabling studies of drug metabolism and toxicity in a controlled setting. Overexpression of PXR or METTL3 can also enhance CYP3A4 induction.
How EDITGENE Supports quinine 3-monooxygenase activity Research
Researchers studying quinine 3-monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in the activity or its regulation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies of CYP3A4, its regulators, and interacting partners.
Contact EDITGENE today to design your custom CRISPR model for quinine 3-monooxygenase activity research.
Frequently Asked Questions About quinine 3-monooxygenase activity
What is quinine 3-monooxygenase activity?
Quinine 3-monooxygenase activity (GO:0050591) is a cytochrome P450 monooxygenase activity that catalyzes the conversion of quinine to 3-hydroxyquinine using NADPH and O2.
What genes are involved in quinine 3-monooxygenase activity?
The primary gene is CYP3A4, which encodes the enzyme cytochrome P450 3A4. Other genes such as POR, PXR, and METTL3 regulate its activity or expression.
Which enzyme catalyzes quinine 3-hydroxylation?
CYP3A4 is the major enzyme responsible for quinine 3-hydroxylation in humans.
How is quinine 3-monooxygenase activity measured?
It is typically measured by incubating quinine with NADPH and enzyme source, then quantifying 3-hydroxyquinine by LC-MS/MS or HPLC.
What is the role of CYP3A4 in drug metabolism?
CYP3A4 metabolizes a large fraction of clinical drugs, including statins and anticancer agents, and its activity influences drug efficacy and toxicity.
How is CYP3A4 expression regulated?
CYP3A4 is transcriptionally regulated by nuclear receptors such as PXR and CAR, and post-transcriptionally by METTL3 and inflammatory cytokines.
Can nitric oxide affect quinine 3-monooxygenase activity?
Yes, nitric oxide can modulate CYP3A4 activity by affecting heme loading in a concentration-dependent manner.
What diseases are associated with altered CYP3A4 activity?
Altered CYP3A4 activity is linked to statin-related myotoxicity, cancer drug resistance, and drug-drug interactions.
How can CRISPR be used to study quinine 3-monooxygenase activity?
CRISPR can generate knockout, point mutation, knock-in, and overexpression models of CYP3A4 and its regulators to dissect their roles.
What model systems are used to study CYP3A4?
Common models include primary human hepatocytes, HepG2 cells, humanized mice, and microengineered liver cultures.
Conclusion
Quinine 3-monooxygenase activity (GO:0050591) is a well-characterized cytochrome P450 activity that serves as a sensitive probe for CYP3A4 function. Its regulation by nuclear receptors, RNA methyltransferases, and nitric oxide underscores the complexity of drug metabolism. Understanding this activity is essential for predicting drug-drug interactions, optimizing therapy, and advancing personalized medicine. CRISPR-based models from EDITGENE provide powerful tools to dissect the genetic and molecular mechanisms controlling quinine 3-monooxygenase activity.
References
- 1. Fernandes V et al.. 2016. Statin-related myotoxicity.. Endocrinol Nutr 63(5):239-49 PMID: 27005745
- 2. Davidson MD et al.. 2017. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development.. Integr Biol (Camb) 9(8):662-677 PMID: 28702667
- 3. Scott EE et al.. 2005. Structures of cytochrome P450 3A4.. Trends Biochem Sci 30(1):5-7 PMID: 15653318
- 4. Das Sinha P et al.. 2025. Nitric oxide regulates cytochrome P450 2D6 and 3A4 activity via concentration-dependent modulation of heme loading.. J Biol Chem 301(11):110772 PMID: 41022321
- 5. Wang J et al.. 2025. METTL3 regulates rifampicin-induced CYP3A4 expression by activating PXR translation and nuclear import and stabilizing CYP3A4 mRNA.. Biochem Pharmacol 239:117016 PMID: 40466953
- 6. Sevrioukova IF et al.. 2015. Anion-Dependent Stimulation of CYP3A4 Monooxygenase.. Biochemistry 54(26):4083-96 PMID: 26066995
- 7. Wang F et al.. 2023. Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy.. Drug Metab Dispos 51(5):543-559 PMID: 36732076
- 8. Crosby M et al.. 2019. Suppression of Hepatic CYP3A4 Expression and Activity by 3-Methylcholanthrene in Humanized PXR-CAR-CYP3A4/3A7 Mice.. Drug Metab Dispos 47(3):279-282 PMID: 30573465
